| Literature DB >> 35155227 |
Peng Gao1, Ping Bai2, Xiangyi Kong1, Yi Fang1, Jidong Gao1, Jing Wang1.
Abstract
BACKGROUND: Implant-based breast reconstruction is increasingly becoming the most common method of postmastectomy breast reconstruction in use today. As the traditional autologous reconstruction technique, latissimus dorsi flap (LDF) is employed by surgeons for reconstruction after breast cancer surgery, including partial mastectomy, modified radical mastectomy, and others. The authors aim to compare patient-reported outcomes (PROs) and complications between the SIS matrix-assisted direct-to-implant (DTI) breast reconstruction and the autologous LDF breast reconstruction.Entities:
Keywords: BREAST-Q version 2.0; biological matrix; breast cancer; direct-to-implant breast reconstruction; latissimus dorsi flap
Year: 2022 PMID: 35155227 PMCID: PMC8828647 DOI: 10.3389/fonc.2022.766076
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1A 42-year-old woman who was diagnosed with invasive carcinoma of the breast and axillary lymph node metastasis. The surgeon was protecting the vessels to separate the latissimus dorsi muscle during latissimus dorsi flap breast reconstruction.
Baseline characteristics of the included patients who received LDF or MLDF breast reconstruction.
| Characteristics | LDF (n = 29) | MLDF (n = 27) | p* |
|---|---|---|---|
| Mean age, years (SD) | 40.34 (9.00) | 38.63 (7.75) | 0.450 |
| Mean BMI, kg/m2 (SD) | 22.76 (2.68) | 25.51 (6.88) | 0.060 |
| Unilateral reconstruction, n (%) | 0.100 | ||
| Right | 16 (55.2) | 9 (33.3) | |
| Left | 13 (44.8) | 18 (66.7) | |
| Tumor size (postoperative pathology), cm (SD) | 2.76 (2.03) | 3.25 (1.60) | 0.320 |
| Tumor location, n (%) | 0.508 | ||
| Upper outer quadrant | 21 (72.4) | 19 (70.4) | |
| Lower outer quadrant | 1 (3.4) | 2 (7.4) | |
| Lower inner quadrant | 4 (13.8) | 1 (3.7) | |
| Upper inner quadrant | 3 (10.3) | 4 (14.8) | |
| Others | 0 | 1 (3.7) | |
| Lymph node management, n (%) | |||
| Axillary resection# | 26 (89.7) | 24 (88.9) | 1.000 |
| Sentinel node | 6 (20.7) | 6 (22.2) | 0.889 |
| Surgical type, n (%) | <0.001 | ||
| NSM | 12 (41.4) | 25 (92.6) | |
| SSM | 17 (58.6) | 2 (7.4) | |
| Duration of surgery, hours (SD) | 3.77 (0.63) | 3.28 (0.69) | 0.008 |
| Time to drain removal#, days (SD) | 27.87 (12.41) | 29.14 (11.26) | 0.691 |
| Treatment, n (%) | |||
| Neoadjuvant chemotherapy | 5 (17.2) | 7 (25.9) | 0.429 |
| Adjuvant chemotherapy | 22 (75.9) | 24 (88.9) | 0.356 |
| Radiotherapy status | 11 (37.9) | 24 (88.9) | <0.001 |
| Hormone therapy | 18 (62.1) | 19 (70.4) | 0.512 |
| Targeted therapy# | 4 (13.8) | 9 (33.3) | 0.157 |
| Smoking status, n (%) | |||
| Former | 2 (6.9) | 2 (7.4) | 1.000 |
| Current | 0 | 0 | |
| Diabetes mellitus, n (%) | 2 (6.9) | 1 (3.7) | 1.000 |
| Mean duration of follow-up at time of BREAST-Q, months (SD) | 75.33 (28.72) | 59.59 (23.03) | 0.096 |
BMI, body mass index; LDF, latissimus dorsi flap; MLDF, mini latissimus dorsi flap; NSM, nipple-sparing mastectomy; SD, standard deviation; SSM, skin-sparing mastectomy.
#Axillary resection means axillary lymph node dissection (ALND). Time to drain removal is the extraction time of the last drainage tube after reconstruction. Targeted therapy means anti-HER2 therapy.
*Statistically significant difference (p < 0.05).
Continuous variables were analyzed using Student’s t-test; categorical variables were analyzed using chi-square test.
Postoperative scales of BREAST-Q Version 2.0 between LDF and MLDF breast reconstruction.
| Items | LDF reconstruction | MLDF reconstruction | p* | ||
|---|---|---|---|---|---|
| Data available, n (%) of N | Mean (SD) | Data available, n (%) of N | Mean (SD) | ||
| Psychosocial well-being | 16 (55.2%) of 29 | 87.69 (18.94) | 19 (70.4%) of 27 | 81.47 (15.69) | 0.296 |
| Satisfaction with breast | 16 (55.2%) of 29 | 56.38 (16.69) | 19 (70.4%) of 27 | 66.00 (14.35) | 0.076 |
| Satisfaction with back | 16 (55.2%) of 29 | 52.50 (29.44) | 19 (70.4%) of 27 | 41.79 (25.11) | 0.254 |
| Physical Well-Being: Back and Shoulder | 16 (55.2%) of 29 | 40.63 (25.00) | 19 (70.4%) of 27 | 38.05 (18.94) | 0.731 |
| Physical well-being: chest | 16 (55.2%) of 29 | 39.31 (24.52) | 19 (70.4%) of 27 | 33.21 (16.11) | 0.384 |
| Sexual well-being | 10 (34.5) of 29 | 70.43 (24.97) | 12 (44.4) of 27 | 69.10 (25.74) | 0.917 |
| Satisfaction with information | 16 (55.2%) of 29 | 66.19 (18.86) | 19 (70.4%) of 27 | 72.05 (19.85) | 0.380 |
| Satisfaction with surgeon | 16 (55.2%) of 29 | 85.38 (27.94) | 19 (70.4%) of 27 | 79.53 (17.54) | 0.456 |
LDF, latissimus dorsi flap; MLDF, mini latissimus dorsi flap; SD, standard deviation.
*Statistically significant difference (p < 0.05).
Student’s t-test was used for each patient-reported outcome measure.
Figure 2Comparison of the back shapes after breast reconstruction at 1 week. The back photograph of a patient who underwent partial mastectomy with mini latissimus dorsi flap breast reconstruction (A). The back photograph of a patient who underwent mastectomy with latissimus dorsi flap breast reconstruction (B).
Univariate analysis results of the complications between LDF breast reconstruction and MLDF breast reconstruction.
| Complications | LDF (n = 29) | MLDF (n = 27) | p* |
|---|---|---|---|
| Major complications, n (%) | 2 (6.9) | 3 (11.1) | 0.664 |
| Minor complications, n (%) | 4 (13.8) | 2 (7.4) | 0.671 |
| Seroma, n (%) | 3 (10.3) | 3 (11.1) | 1.000 |
| Infections, n (%) | 0 | 0 | |
| Recurrence/metastasis, n (%) | 2 (6.9) | 2 (7.4) | 1.000 |
| NAC necrosis, n (%) | 0 | 0 | |
| Chronic pain, n (%) | 1 (3.4) | 0 | 1.000 |
LDF, latissimus dorsi flap; MLDF, mini latissimus dorsi flap; NAC, nipple–areola complex.
*Statistically significant difference (p < 0.05).
Categorical variables were analyzed using chi-square test.
Baseline characteristics of the included patients who received DTI or autologous LDF breast reconstruction.
| Characteristics | SIS matrix-assisted DTI (n = 79) | The whole autologous LDF reconstruction (n = 56) | p* |
|---|---|---|---|
| Mean age, years (SD) | 41.14 (7.03) | 39.52 (8.39) | 0.226 |
| Mean BMI, kg/m2 (SD) | 21.73 (2.20) | 24.08 (5.28) | 0.002 |
| Unilateral reconstruction, n (%) | 0.801 | ||
| Right | 37 (46.8) | 25 (44.6) | |
| Left | 42 (53.2) | 31 (55.4) | |
| Tumor size (postoperative pathology), cm (SD) | 2.35 (1.24) | 3.00 (1.82) | 0.022 |
| Tumor location, n (%) | 0.189 | ||
| Upper outer quadrant | 43 (54.4) | 40 (71.4) | |
| Lower outer quadrant | 14 (17.7) | 3 (5.4) | |
| Lower inner quadrant | 7 (8.9) | 5 (8.9) | |
| Upper inner quadrant | 12 (15.2) | 7 (12.5) | |
| Others | 3 (3.8) | 1 (1.8) | |
| Lymph node management, n (%) | |||
| Axillary resection# | 32 (40.5) | 50 (89.3) | <0.001 |
| Sentinel node | 52 (65.8) | 12 (21.4) | |
| Surgical type, n (%) | 0.227 | ||
| NSM | 59 (74.7) | 37 (66.1) | |
| SSM | 20 (25.3) | 19 (33.9) | |
| Duration of surgery, h (SD) | 2.04 (0.43) | 3.53 (0.70) | <0.001 |
| Time to drain removal#, days (SD) | 22.03 (8.76) | 28.48 (11.78) | <0.001 |
| Treatment, n (%) | |||
| Neoadjuvant chemotherapy | 9 (11.4) | 12 (21.4) | 0.113 |
| Adjuvant chemotherapy | 46 (58.2) | 46 (82.1) | 0.003 |
| Radiotherapy status | 16 (20.3) | 35 (62.5) | <0.001 |
| Hormone therapy | 52 (65.8) | 37 (66.1) | 0.976 |
| Targeted therapy# | 20 (25.3) | 13 (23.2) | 0.779 |
| Smoking status, n (%) | |||
| Former | 4 (5.1) | 2 (3.6) | 1.000 |
| Current | 0 | 0 | |
| Diabetes mellitus, n (%) | 0 | 1 (1.8) | 0.415 |
| Mean duration of follow-up at time of BREAST-Q, months (SD) | 17.55 (4.83) | 66.97 (26.64) | <0.001 |
BMI, body mass index; DTI, direct-to-implant; LDF, latissimus dorsi flap; NSM, nipple-sparing mastectomy; SD, standard deviation; SSM, skin-sparing mastectomy.
#Axillary resection means axillary lymph node dissection (ALND). Time to drain removal is the extraction time of the last drainage tube after reconstruction. Targeted therapy means anti-HER2 therapy.
*Statistically significant difference (p < 0.05).
Continuous variables were analyzed using Student’s t-test; categorical variables were analyzed using chi-square test.
Figure 3Unilateral right nipple-sparing mastectomy with mini latissimus dorsi flap breast reconstruction. A 44-year-old woman who was diagnosed with invasive carcinoma of the right breast and axillary lymph node metastasis before surgery (A, B). Photos at 7 days postoperatively (C, D).
Figure 4Unilateral left nipple-sparing mastectomy and immediate direct-to-implant breast reconstruction with SIS matrix. A 40-year-old woman who was diagnosed with invasive carcinoma and was treated with neoadjuvant chemotherapy before surgery (A, B). Photos at 7 days postoperatively (C, D).
Postoperative scales of BREAST-Q Version 2.0 between DTI and autologous LDF breast reconstruction.
| Items | SIS matrix-assisted DTI | The whole autologous LDF reconstruction | p* | ||
|---|---|---|---|---|---|
| Data available, n (%) of N | Mean (SD) | Data available, n (%) of N | Mean (SD) | ||
| Psychosocial well-being | 68 (86.1%) of 79 | 73.52 (19.96) | 36 (64.3%) of 56 | 84.31 (17.28) | 0.008 |
| Satisfaction with breast | 68 (86.1%) of 79 | 60.27 (17.71) | 36 (64.3%) of 56 | 61.60 (15.99) | 0.710 |
| Physical well-being: chest | 68 (86.1%) of 79 | 39.60 (17.39) | 36 (64.3%) of 56 | 36.00 (20.30) | 0.352 |
| Sexual well-being | 40 (50.6%) of 79 | 50.95 (26.47) | 22 (39.3%) of 56 | 69.65 (24.64) | 0.016 |
| Satisfaction with information | 68 (86.1%) of 79 | 66.79 (18.15) | 36 (64.3%) of 56 | 69.37 (19.35) | 0.507 |
| Satisfaction with surgeon | 68 (86.1%) of 79 | 85.49 (21.38) | 36 (64.3%) of 56 | 82.20 (22.71) | 0.472 |
DTI, direct-to-implant; LDF, latissimus dorsi flap; SD, standard deviation.
SIS matrix (Biodesign Surgisis, Cook Biotech).
*Statistically significant difference (p < 0.05).
Student’s t-test was used for each patient-reported outcome measure.
Univariate analysis results of the complications between DTI and autologous LDF breast reconstruction.
| Complications | SIS matrix-assisted DTI (n = 79) | The whole autologous LDF reconstruction (n = 56) | p* |
|---|---|---|---|
| Major complications, n (%) | 5 (6.3) | 5 (8.9) | 0.570 |
| Minor complications, n (%) | 9 (11.4) | 6 (10.7) | 0.902 |
| Seroma, n (%) | 6 (7.6) | 6 (10.7) | 0.530 |
| Infection, n (%) | 4 (5.1) | 0 | 0.141 |
| Implant loss, n (%) | 5 (6.3) | 0 | 0.076 |
| Metastasis, n (%) | 0 (0) | 4 (7.1) | 0.028 |
| Dehiscence, n (%) | 2 (2.5) | 0 | 0.511 |
| NAC necrosis, n (%) | 2 (2.5) | 0 | 0.511 |
| Chronic pain, n (%) | 2 (2.5) | 1 (1.8) | 1.000 |
DTI, direct-to-implant; LDF, latissimus dorsi flap; NAC, nipple–areola complex.
*Statistically significant difference (p < 0.05).
Categorical variables were analyzed using chi-square test.